CUE

No price yet

Announcements

Nothing here yet

Daily updates

Cue Biopharma reported positive Phase 2 CUE-221 data in chronic spontaneous urticaria, meeting all primary endpoints and the key secondary endpoint at 4 mg/kg with significant placebo-adjusted improvements and a favorable safety profile.Sep 21, 2026

FDA designations

Nothing here yet

News

Cue Biopharma reported positive topline results from the Phase 2 CUE-221 study in chronic spontaneous urticariaSep 21, 2026
Cue Biopharma reported preclinical safety and tolerability data for CUE-401 in autoimmune and inflammatory diseasesFeb 17, 2026
Cue Biopharma and ImmunoScape announce strategic collaboration to develop breakthrough cell therapy approach for solid tumorsNov 6, 2025
Cue Biopharma announces initiation of investigator-sponsored trial of CUE-102 in recurrent glioblastoma multiformeAug 13, 2025
Cue Biopharma reports new complete response and confirms 50% overall response rate in ongoing Phase 1 trial of CUE-101 plus pembrolizumab for recurrent/metastatic HPV+ head and neck cancerJul 16, 2025